ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

telisotuzumab adizutecan

Also written as “Telisotuzumab Adizutecan”, “RC148 plus Telisotuzumab adizutecan” and “ABBV-400”.

In AbbVie’s pipeline, c-Met. Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular, led by 2 companies.

Drug pageTelisotuzumab adizutecan: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 27, 202518 company-led studies, 18 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie1717 open or runningphase 3since May 27, 2025Aug 30, 2021Dec 2026phase 2 · NCT06107413
RemeGenits history only11 open or runningphase 2since Oct 12, 2026Oct 12, 2026Jul 2028phase 2 · NCT07895355
  • Named in AbbVie’s own pipeline as Temab-A (ABBV-400), phase 3, as of Jul 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 4 earlier studies, Aug 30, 2021 to Jun 13, 2024.

  1. Feb 29, 2024Named telisotuzumab adizutecanINNProposed as its International Nonproprietary Name in WHO's List 130 · before, ABBV-400
  2. Sep 25, 2024Phase 2 study in Colorectal NeoplasmsNCT06614192 · 74 enrolled · United States, Australia, Israel and more
  3. Oct 3, 2024Phase 2 study in Adenocarcinoma Of EsophagusNCT06628310 · 185 enrolled · United States, Belgium, Canada and more
  4. Jan 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06772623 · 252 planned · United States, Argentina, Australia and more
  5. Feb 6, 2025Phase 2 study in Colorectal NeoplasmsNCT06820463 · 390 planned · United States, Australia, Austria and more
  6. May 27, 2025Phase 3 study in NeoplasmsNCT07005102 · 854 planned · United States, Australia, Belgium and more
  7. Jun 10, 2025Phase 2 study in Colorectal NeoplasmsNCT07023289 · 140 planned · United States, Belgium, Denmark and more
  8. Aug 28, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07155187 · 490 planned · United States, Australia, Austria and more
  9. Sep 22, 2025Phase 2 study in Solid Tumors Harboring MET AmplificationNCT07196644 · 100 planned · United States, Israel, Japan and more
  10. Mar 13, 2026Phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07490301 · 900 planned · United States, Australia, Israel and more
  11. Apr 7, 2026Phase 3 study in Colorectal NeoplasmsNCT07525206 · 990 planned · United States, Belgium, China and more
  12. Jul 30, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07744126 · 150 planned · United States, Japan, Taiwan
  13. Aug 13, 2026Phase 2 study in NeoplasmsNCT07769502 · 168 planned · United States, Israel, Japan and more
  14. Sep 10, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07821684 · 660 planned
  15. Oct 5, 2026Primary completion moved from 2031-12 to 2036-11Date moved laterphase 3 · +59 months · NCT07005102

Ahead

  1. Dec 2026Primary completion: phase 2 study in NeoplasmsNCT06107413
  2. Aug 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT06614192
  3. Sep 2027Primary completion: phase 1 study in Carcinoma, HepatocellularNCT06084481
  4. Nov 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06772623

TargetBeta

“c-Met”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

All 17 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07821684Carcinoma, Non-Small-Cell Lung3Not yet recruitingMar 2030660
NCT07769502Neoplasms · United States, Israel, Japan and more2RecruitingSep 2028168
NCT07744126Squamous Cell Carcinoma of Head and Neck · United States, Japan, Taiwan2RecruitingOct 2029150
NCT07525206Colorectal Neoplasms · United States, Belgium, China and more3RecruitingMay 2029990
NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma · United States, Australia, Israel and more3RecruitingJun 2031900
NCT07196644Solid Tumors Harboring MET Amplification · United States, Israel, Japan and more2RecruitingDec 2030100
NCT07155187Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingSep 2030490
NCT07023289Colorectal Neoplasms · United States, Belgium, Denmark and more2RecruitingNov 2029140
NCT07005102Neoplasms · United States, Australia, Belgium and more3RecruitingNov 2036854
NCT06820463Colorectal Neoplasms · United States, Australia, Austria and more2RecruitingMar 2028390
NCT06772623Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2RecruitingNov 2027252
NCT06628310Adenocarcinoma Of Esophagus · United States, Belgium, Canada and more2Active, not recruitingOct 2030185
NCT06614192Colorectal Neoplasms · United States, Australia, Israel and more2Active, not recruitingAug 202774
NCT06464692Colorectal Neoplasms · China1Active, not recruitingDec 202731
NCT06107413Neoplasms · United States, Belgium, Germany and more2Active, not recruitingDec 2026280
NCT06084481Carcinoma, Hepatocellular · United States, Australia, Israel and more1RecruitingSep 2027325
NCT05029882Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more1Active, not recruitingNov 2027520

How it is read

Names in the registry

  • “Telisotuzumab Adizutecan”, 12 entries
  • “RC148 plus Telisotuzumab adizutecan”, 4 entries
  • “ABBV-400”, 3 entries
  • “Telisotuzumab adizutecan”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.